Health TrialsbyHealthPanel

Artificial Int: Neurogenic Bowel Education in Spinal Cord Injury Patients

ConditionsSpinal Cord InjuryNeurogenic Bowel Dysfunction
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorSenem Duman

About this trial

The aim of this study is to evaluate the effectiveness of patient education delivered through an artificial intelligence (AI)-based mobile application in the management of neurogenic bowel dysfunction in individuals with spinal cord injury. Within the scope of the study, it will be examined whether the mobile application reduces neurogenic bowel scores, contributes to maintaining stool scores within the normal range, and improves the quality of life of individuals. Accordingly, the AI-based education model to be developed is expected to facilitate the integration of bowel management practices into daily life, prevent complications, and enhance social participation.

\-

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Volunteers who consent to participate.

Age over 18 years.

Diagnosed with spinal cord injury (SCI).

Diagnosed with neurogenic bowel dysfunction (NBD).

Disqualifiers

Individuals with mental retardation.

Individuals with visual and/or hearing impairments.

Individuals with communication problems.

Individuals with a history of additional injuries other than SCI (e.g., head trauma, pelvic injury, pelvic surgery).

Trial design

Design model

Parallel

Treatments tested in this trial

  • Mobil Application

    Other intervention

    After discharge, the documents to be completed will be delivered to the intervention group participants via the mobile application and to the control group participants via WhatsApp. At the end of the study, after the final assessment is completed, participants will be informed of their group allocation, and those in the control group will be provided with access to the mobile application via a WhatsApp link.

Treatment groups

34 Participants
are divided into 2 treatment groups
Group A: Control GroupNo intervention 0 interventions
Group B: intervention groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Change in Neurogenic Bowel Dysfunction (NBD) Score Assessed by the Neurogenic Bowel Dysfunction Scale

Neurogenic bowel dysfunction will be assessed using the Neurogenic Bowel Dysfunction (NBD) Scale, a validated questionnaire for individuals with spinal cord injury. The scale ranges from 0 to 47 points, with higher scores indicating more severe bowel dysfunction. The outcome measure is the change in total NBD score from baseline (Week 0) to Week 12.

Time frame
Baseline (Week 0), Week 4, and Week 12
2

Change in Bowel Care Time Measured in Minutes

Bowel care time will be measured as the average time (in minutes) required to complete bowel care management. Time will be self-reported by participants. The outcome measure is the change in bowel care time from baseline (Week 0) to Week 12.

Time frame
Baseline (Week 0), Week 4, and Week 12

Secondary outcomes

1

Change in Fecal Incontinence Rate

Fecal incontinence will be assessed based on self-reported occurrence of fecal incontinence episodes. The outcome will be expressed as the percentage of participants experiencing fecal incontinence at baseline (Week 0), Week 4, and Week 12.

Time frame
Baseline (Week 0), Week 4, and Week 12

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Senem Duman

Lead sponsor

Saglik Bilimleri Universitesi

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: